inaqovi
otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - Левкемия, миелоид - Антинеопластични средства - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.
gemcitabine - tchaikapharma 200 mg powder for solution for infusion
Чайкафарма Висококачествените Лекарства" АД" - 200 mg powder for solution for infusion
gemcitabine - tchaikapharma 1000 mg powder for solution for infusion
Чайкафарма Висококачествените Лекарства" АД" - 1000 mg powder for solution for infusion
gemcitabine pharma resourses 200 mg powder for solution for infusion
pharma resources gmbh - 200 mg powder for solution for infusion
gemcitabine pharma resourses 1000 mg powder for solution for infusion
pharma resources gmbh - 1000 mg powder for solution for infusion
gemcitabine csc 200 mg powder for solution for infusion
gp pharm, s.a. - 200 mg powder for solution for infusion
gemcitabine csc 1 000 mg powder for solution for infusion
gp pharm, s.a. - 1 000 mg powder for solution for infusion
gemcitabine accord 100 mg/ml concetrate for solution for infusion
accord healthcare limited - 100 mg/ml concetrate for solution for infusion
dacogen
janssen-cilag international n.v. - децитабин - Левкемия, миелоид - Антинеопластични средства - Лечение на възрастни пациенти с новодиагностицираните de novo или вторична остра миелоидна левкемия (aml) според класификацията на Световната здравна организация (СЗО), които не са кандидатки за стандартен индукционна химиотерапия.